USP standards build trust in biologics and biosimilars ...
The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health.
We see their names – ending in “mab” – in TV ads for treating everything from skin conditions to cancer.
The emergence of COVID-19 almost five years ago forced us all to face the realities of containing and mitigating a highly transmissible, deadly pandemic.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
U.S. Pharmacopeia (USP) brought together preeminent thought leaders from industry, global health organizations, regulatory agencies, standards setting organizations and other stakeholders at its virtual Global Biologics Summit on June 11, 2020.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
The spread of COVID-19 has been a wake-up call to the world about dangers posed by over-reliance on single-country sources in the global medicine supply chain.
Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.